- ICH GCP
- Реестр клинических исследований США
- Клиническое испытание NCT00462761
A Phase I Study of AC220 in Patients With Relapsed/Refractory Acute Myeloid Leukemia Regardless of FLT3 Status
Phase I Open-Label, Sequential Dose Escalation Study Investigating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AC220 When Administered Daily to Patients With Relapsed or Refractory Acute Myeloid Leukemia
Обзор исследования
Статус
Вмешательство/лечение
Подробное описание
Тип исследования
Регистрация (Действительный)
Фаза
- Фаза 1
Контакты и местонахождение
Места учебы
-
-
-
T'Bilisi, Грузия
- Chemotherapy and Immunotherapy Clinic
-
T'bilisi, Грузия
- Hematology and Chemotherapy Clinic
-
-
-
-
Alabama
-
Birmingham, Alabama, Соединенные Штаты, 35294
- University of Alabama at Birmingham
-
-
Nebraska
-
Omaha, Nebraska, Соединенные Штаты, 68198
- University of Nebraska Medical Center
-
-
Texas
-
Houston, Texas, Соединенные Штаты, 77030
- MD Anderson Cancer Center
-
-
Критерии участия
Критерии приемлемости
Возраст, подходящий для обучения
Принимает здоровых добровольцев
Полы, имеющие право на обучение
Описание
Inclusion Criteria:
- Males and females age ≥ 18 years;
Histopathologically documented primary or secondary AML, as defined by WHO criteria (Jaffe et al, 2001), confirmed by pathology review at treating institution, meeting at least one of the following:
- Refractory to at least 1 cycle of induction chemotherapy, or
- Relapsed after at least 1 cycle of induction chemotherapy, or
- Patient is not, according to the clinical judgment of the Principal Investigator, a candidate for induction chemotherapy due to age, comorbidity, or other factors;
- Patients for whom no standard therapies are anticipated to result in a durable remission, or who have failed potentially curative therapy, or who refuse standard therapy or patients for whom there is no known therapy of documented treatment benefit;
- Eastern Cooperative Oncology Group (ECOG) performance status of 0-3;
- In the absence of rapidly progressing disease, the interval from prior treatment to time of AC220 administration should be at least 2 weeks for cytotoxic agents (other than hydroxyurea, per Section 8.8), or at least 5 half-lives for noncytotoxic agents;
- Persistent chronic clinically significant toxicities from prior chemotherapy or surgery must be less than Grade 2;
- Serum creatinine ≤ 2.0 mg/dL;
- Total serum bilirubin ≤ 1.5 × ULN unless considered due to Gilbert's syndrome or leukemic organ involvement;
- Serum AST or ALT ≤ 3.0 × ULN unless considered due to leukemic organ involvement;
- Females of childbearing potential must have a negative pregnancy test (urine β-hCG);
- Females of childbearing potential and sexually mature males must agree to use a medically accepted method of contraception throughout the study;
- Written informed consent must be provided.
Exclusion Criteria:
- Histologic diagnosis of acute promyelocytic leukemia;
- Clinically active central nervous system leukemia;
- Persistent clinically significant toxicity from prior chemotherapy that is Grade 2 or higher by the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE v3);
- Bone marrow transplant within 2 months prior to study;
- Active, uncontrolled infection;
- Major surgery within 4 weeks prior to study;
- Radiation therapy within 4 weeks prior to, or concurrent with, study;
- Human immunodeficiency virus positivity;
- Active hepatitis B or C or other active liver disease;
- Women who are pregnant, lactating, or unwilling to use contraception if of childbearing potential;
- Medical condition, serious intercurrent illness, or other extenuating circumstance that, in the judgment of the Principal Investigator, could jeopardize patient safety or interfere with the objectives of the study.
Учебный план
Как устроено исследование?
Детали дизайна
- Основная цель: Уход
- Распределение: Н/Д
- Интервенционная модель: Одногрупповое задание
- Маскировка: Нет (открытая этикетка)
Оружие и интервенции
Группа участников / Армия |
Вмешательство/лечение |
---|---|
Экспериментальный: AC220
Determine safety, tolerability and pharmacokinetic (PK) parameters of AC220
|
Powder in bottle formulation supplied as 50mg or 350 mg in glass, crimped serum vials.
Requires reconstitution by a pharmacist, and must be stored securely and protected from light.
Другие имена:
|
Что измеряет исследование?
Первичные показатели результатов
Мера результата |
Временное ограничение |
---|---|
Number of Participants With Treatment-Emergent Treatment Related Adverse Events Following Oral Administration of Quizartinib in Participants With Relapsed or Refractory Acute Myeloid Leukemia
Временное ограничение: Baseline up to 30 days post last dose
|
Baseline up to 30 days post last dose
|
Number of Participants With Treatment-emergent Treatment-related Grade 3 or 4 Adverse Events By At Least 10% of All Participants By Dose Group Following Oral Administration of Quizartinib in Participants With Relapsed or Refractory Acute Myeloid Leukemia
Временное ограничение: Baseline up to 30 days post last dose
|
Baseline up to 30 days post last dose
|
Вторичные показатели результатов
Мера результата |
Мера Описание |
Временное ограничение |
---|---|---|
Number of Participants Achieving a Best Disease Response by Dose Cohort in Terms of Progressive Disease Following Oral Administration of Quizartinib in Participants With Relapsed or Refractory Acute Myeloid Leukemia
Временное ограничение: Baseline up to 28 days after the last dose, up to approximately 3 years
|
Progressive disease response criteria included doubling of blast count % in bone marrow (biopsy or aspirate) from baseline; considering measurements starting on Study Day 15, doubling of blast count % in blood from baseline; death determined to be related to disease or disease progression; and investigator reported disease progression.
|
Baseline up to 28 days after the last dose, up to approximately 3 years
|
Number of Participants Achieving a Best Disease Response by Dose Cohort in Terms of Best Overall Response Following Oral Administration of Quizartinib in Participants With Relapsed or Refractory Acute Myeloid Leukemia
Временное ограничение: Baseline up to 28 days after the last dose, up to approximately 3 years
|
Complete Response (CR) response criteria included either a post-baseline bone marrow (BM) biopsy or aspiration % blasts <5%, absolute neutrophil count (ANC) >1×10^9/L and platelet count >100×10^9/L on the same date as the qualifying BM assessment.
CRp response included all CR criteria met, except participant did not experience a platelet recovery (ANC recovery required).
CRi response included a qualifying BM result, but not an ANC recovery.
Participants may or may not have had a platelet recovery and were not required to be transfusion independent.
Partial remission (PR) response included a decrease of ≥50% in % blasts in the BM aspirate or biopsy from baseline to a post-baseline result between 5% to 25% in the bone marrow aspirate or biopsy.
Nonresponders (NR) had a pre- and 1 or more post-baseline BM assessment carried out, but results did not meet any response criteria.
Participants who were not evaluable (NE) did not have at least 14 days of treatment and were not assessed.
|
Baseline up to 28 days after the last dose, up to approximately 3 years
|
Number of Participants Achieving a Best Disease Response by Dose Cohort in Terms of Best Overall Response Following Oral Administration of Quizartinib in Participants With Relapsed or Refractory Acute Myeloid Leukemia
Временное ограничение: Baseline up to 28 days after the last dose, up to approximately 3 years
|
Complete Response (CR) response criteria included either a post-baseline bone marrow biopsy or aspiration % blasts <5%, absolute neutrophil count (ANC) >1×10^9/L and platelet count >100×10^9/L on the same date as the qualifying bone marrow assessment.
CRp response included all CR criteria met except participant did not experience a platelet recovery.
Participants must have experienced an ANC Recovery.
CRi response included a qualifying bone marrow result, but did not experience an ANC recovery.
Participants may or may not have experienced a platelet recovery and were not required to be transfusion independent.
Partial remission (PR) response included a decrease of ≥50% in % blasts in the bone marrow aspirate or biopsy from baseline to a post-baseline result between 5% to 25% in the bone marrow aspirate or biopsy.
Nonresponders (NR) had a pre- and 1 or more post-baseline bone marrow assessment carried out, but results did not meet any of the CR or PR or progressive disease criteria.
|
Baseline up to 28 days after the last dose, up to approximately 3 years
|
Number of Participants With Hematologic Improvement Following Oral Administration of Quizartinib in Participants With Relapsed or Refractory Acute Myeloid Leukemia
Временное ограничение: Baseline up to 28 days after the last dose, up to approximately 3 years
|
Hematologic improvement is summarized in terms of Erythroid Response (HI-E), Platelet Response (HI-P), Neutrophil Response (HI-N), and Hematologic Improvement (HI). For post-treatment results, HI-E major responders had >2 g/dL increase in hemoglobin for at least 1 result after first treatment and transfusion independent; minor responders 1 to 2 g/dL increase in hemoglobin for at least 1 result post first treatment and a 50% decrease in red blood cell transfusion requirements. For HI-P, major responders had ≥30 × 10^9/L increase in platelet count and transfusion independent; minor responders had 50% or more increase in platelet count with a net increase between 10 to 30 × 10^9/L and 50% decrease in platelet transfusion requirements. For HI-N, major responders had an increase in absolute neutrophil count (ANC) of 100% or an absolute increase of more than 0.5 × 10^9/L (whichever is greater); minor responders had an increase in ANC of 100% but an absolute increase of <0.5 × 10^9/L. |
Baseline up to 28 days after the last dose, up to approximately 3 years
|
Соавторы и исследователи
Спонсор
Публикации и полезные ссылки
Даты записи исследования
Изучение основных дат
Начало исследования
Первичное завершение (Действительный)
Завершение исследования (Действительный)
Даты регистрации исследования
Первый отправленный
Впервые представлено, что соответствует критериям контроля качества
Первый опубликованный (Оценивать)
Обновления учебных записей
Последнее опубликованное обновление (Действительный)
Последнее отправленное обновление, отвечающее критериям контроля качества
Последняя проверка
Дополнительная информация
Термины, связанные с этим исследованием
Ключевые слова
- острый
- фармакокинетика
- ПК
- фармакокинетический
- фармакодинамика
- рецидив
- огнеупорный
- миелофиброз
- ингибитор
- фармакодинамический
- тирозин
- ПД
- киназа
- дисплазия
- мутации
- FLT3
- миелоидный
- рецептор
- РТК
- AC220
- класс III
- т(8;21)
- заявка(16)
- 11q23
- моноцитарный
- q22;q22
- AML1/ETO
- t(16;16
- p13;q22
- CBFbeta/MYH11
- p13q22
- myelomonocytic
- monoblastic
- erythroid
- erythroleukemia
- megakaryoblastic
- basophilic
- panmyelosis
Дополнительные соответствующие термины MeSH
Другие идентификационные номера исследования
- CP0001
Планирование данных отдельных участников (IPD)
Планируете делиться данными об отдельных участниках (IPD)?
Описание плана IPD
Сроки обмена IPD
Критерии совместного доступа к IPD
Совместное использование IPD Поддерживающий тип информации
- STUDY_PROTOCOL
- САП
- КСО
Эта информация была получена непосредственно с веб-сайта clinicaltrials.gov без каких-либо изменений. Если у вас есть запросы на изменение, удаление или обновление сведений об исследовании, обращайтесь по адресу register@clinicaltrials.gov. Как только изменение будет реализовано на clinicaltrials.gov, оно будет автоматически обновлено и на нашем веб-сайте. .
Клинические исследования AC220
-
Daiichi Sankyo Co., Ltd.Завершенный
-
Daiichi Sankyo, Inc.Ambit Biosciences CorporationЗавершенныйЛейкоз, Миелоидный, ОстрыйСоединенные Штаты, Франция, Италия, Соединенное Королевство
-
Daiichi Sankyo Co., Ltd.ЗавершенныйОстрый миелоидный лейкоз (ОМЛ)Китай
-
Daiichi Sankyo, Inc.ПрекращеноОстрый миелоидный лейкозСоединенные Штаты
-
Daiichi Sankyo, Inc.Ambit Biosciences CorporationЗавершенныйЛейкоз, Миелоидный, ОстрыйСоединенные Штаты
-
Daiichi Sankyo, Inc.ЗавершенныйОстрый миелоидный лейкозСоединенные Штаты, Испания, Нидерланды, Канада, Франция, Германия, Соединенное Королевство, Италия, Польша
-
Daiichi Sankyo, Inc.ЗавершенныйСолидные опухолиСоединенные Штаты
-
Children's Oncology GroupNational Cancer Institute (NCI)ЗавершенныйДетский острый миелоидный лейкоз/другие миелоидные злокачественные новообразованияСоединенные Штаты
-
Daiichi Sankyo, Inc.ЗавершенныйПОДСоединенные Штаты, Корея, Республика, Тайвань, Соединенное Королевство, Франция, Австралия, Испания, Италия, Канада, Сингапур, Германия, Нидерланды, Гонконг, Бельгия, Хорватия, Чехия, Венгрия, Польша, Сербия
-
University Hospital HeidelbergDaiichi Sankyo Europe, GmbH, a Daiichi Sankyo CompanyОтозван